rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
7
|
pubmed:dateCreated |
2002-12-18
|
pubmed:abstractText |
The EPISTENT and EPIC studies demonstrated a reduction of clinically driven re-interventions after percutaneous transluminal coronary angioplasty (PTCA) and stent implantation in patients treated with abciximab, while for tirofiban no similar effects could be demonstrated. This may be explained by the different effects on the migratory and invasive potential of vascular smooth muscle cells (VSMCs) by integrin alpha v beta 3 blockade. Therefore, the objective of this study was to compare the effectiveness of abciximab and tirofiban to affect VSMC migration and invasion.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0954-6928
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
13
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
357-64
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12488644-Analysis of Variance,
pubmed-meshheading:12488644-Antibodies, Monoclonal,
pubmed-meshheading:12488644-Binding, Competitive,
pubmed-meshheading:12488644-Cell Movement,
pubmed-meshheading:12488644-Cells, Cultured,
pubmed-meshheading:12488644-Chemotaxis,
pubmed-meshheading:12488644-Coronary Vessels,
pubmed-meshheading:12488644-Humans,
pubmed-meshheading:12488644-Immunoglobulin Fab Fragments,
pubmed-meshheading:12488644-Integrin alphaVbeta3,
pubmed-meshheading:12488644-Muscle, Smooth, Vascular,
pubmed-meshheading:12488644-Tyrosine
|
pubmed:year |
2002
|
pubmed:articleTitle |
Decrease of vascular smooth muscle cell locomotion by abciximab, but not tirofiban: a possible role of different affinity to alpha v beta 3 integrins.
|
pubmed:affiliation |
University Hospital, Aachen, Medical Clinic I, Regensburg, Germany. ruediger.blindt@post.rwth-aachen.de
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|